OneVision: Retinal Camera with Integrated Machine Learning Screening and Diagnostics

Oivi's team of skilled and innovative engineers is developing a ground-breaking technology for screening disease conditions that threaten vision. The first disease they will focus is a retinal disease called "Diabetic Retinopathy" (DR). The technology is based on Norway's first retinal camera developed by Oivi AS, and includes functionality for automated image taking and diagnosis using artificial intelligence. DR is the leading cause of preventable blindness in adults worldwide. With around 537 million people affected by diabetes globally, and numbers are expected to rise to 650 million by 2045, DR is a growing concern. After two years of diabetes, 81% of patients will experience some degree of DR. However, early screening and timely treatment can prevent vision loss in over 95% of cases. Detecting diabetic retinopathy in the early stages is challenging, as it often causes no symptoms. Screening is therefore essential to identify at-risk patients and prevent blindness. Despite recommendations from the American Diabetes Association, only 50% of diabetic patients in developed countries undergo annual screenings. The gold standard for diagnosing DR is expensive and often unavailable in remote or developing regions. The Oivi camera addresses this gap by offering automated image capture, making comprehensive screening possible. Oivi simplifies screening, early diagnosis and by detecting the course of the disease early, the treatment options will often be much more cost-effective. This will be able to reduce the cases of vision loss considerably. The initial market includes countries such as India, where access to screening is limited. The Oivi camera and service will provide a more affordable alternative to existing retinal cameras, making it available to primary care and diabetes clinics worldwide.

The team is building an integrated screening ophthalmic device to detect preventable vision threatening pathologies, with the first focus being Diabetic Retinopathy (DR), to be used at a point-of-care. The solution will be based on Oivi AS' successful development of Norway's first retinal camera, from a previous project, and will further integrate artificial intelligence to automated image capture. The project will be a stepping stone for tackling +39 degenerative retinal conditions using machine learning. DR is a microvascular complication of diabetes caused by long term damage due to uncontrolled blood glucose levels. It is the leading cause of preventable blindness among adults. An estimated 537 million people globally are affected by diabetes and this number is projected to increase to 650 million by 2045. Within 10 years of onset 81% of diabetics will have some degree of DR, but over 95% of patients in vision loss can be prevented with early screening and timely treatment. Diabetic retinopathy is difficult to diagnose in its early stages as it is asymptomatic, and hence, screening is the only way to identify such patients to prevent them from going blind. In the developed world only 50% of patients with diabetes get screenings in a given year despite recommendations by the American Diabetes Association. The gold standard of diagnosing DR is expensive and often unavailable in remote or developing parts of the world. The Oivi camera addresses these unmet needs with its automated image capture and diagnosis thereby enabling widespread screening. Oivi enables early diagnosis and inexpensive and early treatment options, thus significantly preventing vision loss. Initial plans are emerging markets like India, where the population has very limited screening. The Oivi device and service will have significant cost advantages compared to existing retinal cameras thereby expanding the market to the vast majority of primary care facilities and diabetic clinics.